yttrium radioisotopes has been researched along with Lymphoma, B-Cell in 89 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (5.62) | 18.2507 |
| 2000's | 64 (71.91) | 29.6817 |
| 2010's | 17 (19.10) | 24.3611 |
| 2020's | 3 (3.37) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, I; Ito, T; Okada, M | 1 |
| Bellò, M; Benevolo, G; Bisi, G; Boccomini, C; Botto, B; Castellino, A; Chiappella, A; Ciochetto, C; Freilone, R; Nicolosi, M; Orsucci, L; Passera, R; Pecoraro, C; Pregno, P; Vitolo, U | 1 |
| Bodet-Milin, C; Cascini, GL; Cicone, F; Kolstad, A; Kraeber-Bodéré, F; Santo, G; Stokke, C | 1 |
| Buck, AK; Dreher, N; Einsele, H; Higuchi, T; Kraus, S; Rasche, L; Samnick, S; Serfling, SE; Werner, RA | 1 |
| Green, DJ; Press, OW | 1 |
| Cassaday, RD; Flowers, ME; Gopal, AK; Green, DJ; Guthrie, KA; Maloney, DG; Pagel, JM; Press, OW; Rajendran, JG; Rezvani, AR; Sandmaier, BM; Sorror, ML; Storb, RF; Storer, BE | 1 |
| Khouri, IF | 1 |
| Bourgeois, P; Bron, D; Everaert, H; Flamen, P; Ghanem, G; Guiot, T; Meuleman, N; Muylle, K; Vaes, M; van Dongen, GA; Vanderlinden, B; Vugts, DJ | 1 |
| Ganapathy, S; Ha, CS; Li, X; Su, H; Yuan, ZM | 1 |
| Bal, CS; Gupta, SK; Malhotra, A; Sharma, A; Singla, S; Snehlata, EY; Thakral, P; Tyagi, JS; Vashist, A; Yadav, MP | 1 |
| Assaf, C; Beyer, M; Gellrich, S; Maza, S; Munz, DL; Orawa, H; Spilker, L; Steinhoff, M; Sterry, W | 1 |
| Bruland, OS; Dahle, J; Larsen, RH | 1 |
| Czuczman, MS; Goldenberg, DM; Karacay, H; Mattes, MJ; Sharkey, RM | 1 |
| Endo, K; Hayashi, M; Hotta, T; Ishizawa, K; Itoh, K; Matsuno, Y; Matsusako, M; Mori, S; Morishima, Y; Nakamura, S; Nawano, S; Ogura, M; Ohashi, Y; Okamoto, S; Okumura, H; Taniwaki, M; Terauchi, T; Tobinai, K; Tsukamoto, N; Watanabe, T | 1 |
| Hamm, B; Jahnke, K; Kiewe, P; Korfel, A; Maza, S; Munz, DL; Thiel, E | 1 |
| Kinuya, S | 1 |
| De Falco, T; De Renzo, A; Erra, P; Klain, M; Nardelli, A; Pace, L; Pellegrino, T; Perna, F; Rotoli, B; Speranza, A; Storto, G | 1 |
| Bardiès, M; Bodet-Milin, C; Ferrer, L; Goldenberg, DM; Kraeber-Bodéré, F; Le Gouill, S; Rousseau, C; Wegener, WA | 1 |
| Argnani, L; Baccarani, M; Broccoli, A; Derenzini, E; Fanti, S; Fina, M; Gandolfi, L; Montini, GC; Pellegrini, C; Pileri, S; Stefoni, V; Zinzani, PL | 1 |
| Deptala, A; Hohloch, K; Jurczak, W; Linkesch, W; Lorsbach, M; Truemper, LH; Windemuth-Kiesselbach, C; Wulf, GG; Zinzani, PL | 1 |
| Doolittle, ND; Dósa, E; Kraemer, DF; Lewin, SJ; Muldoon, LL; Neuwelt, EA; Pagel, MA | 1 |
| Chiesa, C; Dewaraja, YK; Lindén, O; Ljungberg, M; Sjögreen-Gleisner, K; Strand, SE; Tennvall, J | 1 |
| de Rooij, M; Huijgens, PC; Visser, OJ; Wondergem, MJ; Zijlstra, JM; Zweegman, S | 1 |
| Tomblyn, M | 1 |
| Giza, A; Hubalewska-Dydejczyk, A; Jakóbczyk, M; Jurczak, W; Skotnicki, AB; Sobociński, M; Staszczak, AS; Szostek, M; Zimowska-Curyło, D | 1 |
| Gleisner, KS; Ljungberg, M | 1 |
| Ahmadi, MA; Esmaeli, B; McLaughlin, P; Murray, JL; Naderi, A; Romaguera, J; Singh, S; White, CA | 1 |
| Ansell, SM; Habermann, TM; Ristow, KM; Wiseman, GA; Witzig, TE | 1 |
| Juweid, ME | 1 |
| Axworthy, D; Hedin, N; Mallet, R; Matthews, DC; Meyer, D; Pagel, JM; Press, OW; Subbiah, K; Theodore, LJ; Wilbur, DS | 1 |
| Fisher, DR; Goldenberg, DM; Govindan, SV; Griffiths, GL; Sharkey, RM | 1 |
| Fink-Bennett, DM; Thomas, K | 1 |
| Hernandez, MC; Knox, SJ | 2 |
| Witzig, TE | 4 |
| Gregory, SA | 1 |
| Gordon, LI | 1 |
| Horning, SJ | 1 |
| Zimmer, AM | 1 |
| Darif, M; Emmanouilides, C; Gordon, LI; Molina, A; Raubtischek, A; Schilder, RJ; White, CA; Wiseman, G; Witzig, T | 1 |
| Keating, MJ; Murray, JL; O'Brien, S; Tsimberidou, AM; Wierda, WG | 1 |
| Byar, K; Riley, MB | 1 |
| Gordon, LI; Riley, MB | 1 |
| Hendrix, C | 1 |
| Byar, K | 1 |
| Ghobrial, I; Witzig, T | 1 |
| Macklis, RM | 3 |
| Bartlett, N; Czuczman, M; Darif, M; Emmanouilides, C; Gordon, LI; Joyce, R; Molina, A; Pohlman, B; Theuer, C; Vo, K; White, C; Wiseman, G; Witzig, T | 1 |
| Bartlett, N; Gordon, L; Molina, A; Murray, J; Schilder, R; Spies, S; Wang, H; White, C; Wiseman, G; Witzig, T | 1 |
| Wiseman, GA; Witzig, TE | 1 |
| Coleman, M; Furman, RR; Leonard, JP; Ruan, J | 1 |
| Gokhale, AS; Macklis, RM; Mayadev, J; Pohlman, B | 1 |
| Cavallin-Ståhl, E; Garkavij, M; Kurkus, J; Lindén, O; Ljungberg, M; Nilsson, R; Ohlsson, T; Sandberg, B; Strand, SE; Tennvall, J | 1 |
| de Nully Brown, P; Hansen, M; Jurlander, J; Lindén, O | 1 |
| Dierckx, RA; Otte, A | 1 |
| Leonard, JP | 1 |
| Endo, K; Hayashi, M; Igarashi, T; Itoh, K; Kobayashi, Y; Kusumoto, S; Nakata, M; Nawano, S; Sekiguchi, N; Seriu, T; Tanimoto, K; Terauchi, T; Terui, S; Tobinai, K; Usubuchi, N; Watanabe, T | 1 |
| Biersack, HJ; Brockmann, H | 1 |
| Darif, M; Emmanouilides, C; Flinn, IW; Gordon, LI; Molina, A; Schilder, RJ; Vo, K; Wiseman, GA; Witzig, TE | 1 |
| Tobinai, K | 3 |
| Knox, SJ; Meredith, RF | 1 |
| DeNardo, GL; DeNardo, SJ; Sysko, VV | 1 |
| Darif, M; Emmanouilides, C; Flinn, IW; Gordon, LI; Macklis, R; Molina, A; Schilder, RJ; Vo, K; Wiseman, GA; Witzig, TE | 1 |
| Hess, G; Huglo, D; Illidge, T; Kalmus, J; Liberati, AM; Marcus, R; Martinelli, G; Milpied, N; Morschhauser, F; Paganelli, G; Rule, S; Stein, H; Zinzani, PL | 1 |
| Armitage, JO; Bierman, PJ; Bociek, RG; Loberiza, FR; Matso, D; Vose, JM | 1 |
| Borrebaek, J; Bruland, ØS; Dahle, J; Hjelmerud, AK; Jonasdottir, TJ; Larsen, RH; Melhus, KB; Press, OW | 1 |
| Awasthi, S; Buchholz, W; Chung, H; Egner, J; Forero, A; Gregory, S; Harrough, VD; Jacobs, S; Jasthy, S; Krumdieck, R; Lister, J; Lobuglio, AF; Maggass, G; McKay, C; Meredith, R; Mueh, J; Saville, W; Shah, J; Shen, S; Tharp, M; Wang, W; Winter, C | 1 |
| Bartolomei, M; Cremonesi, M; Ferrari, M; Ferrucci, PF; Grana, CM; Martinelli, G; Paganelli, G; Papi, S; Prisco, G; Stabin, M; Vanazzi, A | 1 |
| Colletti, PM; Conti, PS; Ulaner, GA | 1 |
| Gopal, AK; Maloney, DG; Pagel, JM; Press, OW; Wilbur, SM | 1 |
| Collins, HA; Halpern, SE; Hupf, HB; Miller, RA; Parker, BA; Royston, I; Shawler, DL; White, CA | 1 |
| Becker, M; Chinn, P; Davis, T; Deb, N; Fowler, S; Goris, ML; Grillo-López, A; Knox, SJ; Levy, R; Liles, TM; Marquez, C; Negrin, R; Ning, SC; Trisler, K; Varns, C | 1 |
| Anderson, DR; Chinn, PC; Hanna, N; Leonard, JE; Rosenberg, J | 1 |
| Press, OW | 1 |
| Dallaire, BK; Grillo-López, AJ; McClure, A; Shen, D; Varns, C; Wei, A; White, CA | 1 |
| Belanger, R; Berlfein, JR; Dahlbom, M; Ding, E; Dunn, WL; Erwin, W; Grillo-López, AJ; Karvelis, K; Raubitschek, A; Schultheiss, T; Silverman, DH; Spies, S; Stabin, M; White, CA; Wiseman, GA; Witzig, TE | 1 |
| Goldenberg, DM; Mattes, MJ; Ochakovskaya, R; Osorio, L | 1 |
| Cripe, L; Czuczman, MS; Emmanouilides, C; Emmanuolides, C; Flinn, IW; Gordon, LI; Grillo-López, AJ; Olejnik, T; Saleh, M; Silverman, DH; Spies, SS; White, CA; Wiseman, GA; Witzig, TE | 1 |
| Bartlett, NL; Cabanillas, F; Czuczman, MS; Emmanouilides, C; Gordon, LI; Grillo-López, AJ; Joyce, R; Multani, P; Padre, N; Pohlman, BL; White, CA; Wiseman, GA; Witzig, TE | 1 |
| Alcindor, T; Witzig, TE | 1 |
32 review(s) available for yttrium radioisotopes and Lymphoma, B-Cell
| Article | Year |
|---|---|
Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update.
Topics: Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Yttrium Radioisotopes | 2023 |
Whither Radioimmunotherapy: To Be or Not To Be?
Topics: Antibodies, Monoclonal; Humans; Immunoconjugates; Lymphoma, B-Cell; Radioimmunotherapy; Radiopharmaceuticals; Yttrium Radioisotopes | 2017 |
Dosimetry in patients with B-cell lymphoma treated with [(90)Y]ibritumomab tiuxetan or [(131)I]tositumomab.
Topics: Antibodies, Monoclonal; Antigens, CD20; Bone Marrow; Dose-Response Relationship, Radiation; Female; Humans; Iodine Radioisotopes; Lymphoma, B-Cell; Male; Radioimmunotherapy; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2011 |
Radioimmunotherapy for B-cell non-hodgkin lymphomas.
Topics: Antibodies, Monoclonal; Humans; Iodine Radioisotopes; Lymphoma, B-Cell; Radioimmunotherapy; Radiopharmaceuticals; Yttrium Radioisotopes | 2012 |
Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Agents; Combined Modality Therapy; Humans; Immunotherapy; Lymphoma, B-Cell; Radioimmunotherapy; Radioisotopes; Radiotherapy Dosage; Rituximab; Yttrium Radioisotopes | 2002 |
90Y-ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Humans; Lymphoma, B-Cell; Neoplasm Recurrence, Local; Palliative Care; Radiation Protection; Radioimmunotherapy; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Yttrium Radioisotopes | 2003 |
Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin).
Topics: Antibodies, Monoclonal; Antigens, CD20; Antigens, Neoplasm; Apoptosis; Cell Cycle; Dose-Response Relationship, Radiation; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Yttrium Radioisotopes | 2003 |
Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antigens, CD20; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Recurrence; Risk Factors; Thrombocytopenia; Yttrium Radioisotopes | 2003 |
Selecting patients for treatment with 90Y ibritumomab tiuxetan (Zevalin).
Topics: Antibodies, Monoclonal; Antigens, CD20; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Neutropenia; Patient Selection; Thrombocytopenia; Yttrium Radioisotopes | 2003 |
Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Topics: Antibodies, Monoclonal; Antigens, CD20; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Patient Care Team; Patient Selection; Radioimmunotherapy; Safety; Yttrium Radioisotopes | 2003 |
Future directions in radioimmunotherapy for B-cell lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Rituximab; Yttrium Radioisotopes | 2003 |
Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Topics: Antibodies, Monoclonal; Humans; Lymphoma, B-Cell; Nuclear Medicine; Physician's Role; Radiation Protection; Radioimmunotherapy; Yttrium Radioisotopes | 2004 |
Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Clinical Trials as Topic; Humans; Lymphoma, B-Cell; Radioimmunotherapy; Yttrium Radioisotopes | 2004 |
The rationale for and background of radioimmunotherapy: an emerging therapy for B-cell non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Agents; Controlled Clinical Trials as Topic; Dose-Response Relationship, Radiation; Humans; Lymphoma, B-Cell; Radioimmunotherapy; Radiotherapy Dosage; Yttrium Radioisotopes | 2004 |
Efficacy and safety of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Topics: Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Agents; Controlled Clinical Trials as Topic; Dose-Response Relationship, Radiation; Humans; Lymphoma, B-Cell; Nursing Methodology Research; Oncology Nursing; Patient Education as Topic; Radioimmunotherapy; Radiotherapy Dosage; Yttrium Radioisotopes | 2004 |
Radiation safety with yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy.
Topics: Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Agents; Dose-Response Relationship, Radiation; Humans; Lymphoma, B-Cell; Nursing Methodology Research; Oncology Nursing; Patient Education as Topic; Radiation Injuries; Radioimmunotherapy; Risk Factors; Safety; Yttrium Radioisotopes | 2004 |
Educating patients about radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Topics: Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Agents; Antineoplastic Protocols; Dose-Response Relationship, Radiation; Humans; Lymphoma, B-Cell; Nurse-Patient Relations; Nursing Methodology Research; Oncology Nursing; Patient Education as Topic; Radiation Injuries; Radioimmunotherapy; Risk Factors; Treatment Outcome; Yttrium Radioisotopes | 2004 |
Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Agents; Clinical Trials as Topic; Humans; Iodine Radioisotopes; Lymphoma, B-Cell; Radioimmunotherapy; Yttrium Radioisotopes | 2004 |
Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Humans; Iodine Radioisotopes; Lymphoma, B-Cell; Prednisone; Radiation-Sensitizing Agents; Radiobiology; Radioimmunotherapy; Vincristine; Yttrium Radioisotopes | 2004 |
New developments in immunotherapy for non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Humans; Immunotherapy; Interleukin-2; Lymphoma; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Rituximab; Yttrium Radioisotopes | 2005 |
[Radioimmunotherapy with (90)Y-Ibritumomab tiuxetan].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials as Topic; Contraindications; Humans; Lymphoma, B-Cell; Radioimmunotherapy; Treatment Outcome; Yttrium Radioisotopes | 2006 |
[Radioimmunotherapy for B-cell lymphoma].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Humans; Iodine Radioisotopes; Lymphoma, B-Cell; Mice; Radioimmunotherapy; Rituximab; Yttrium Radioisotopes | 2006 |
Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antigens, CD20; Humans; Iodine Radioisotopes; Lymphoma, B-Cell; Radioimmunotherapy; Transplantation Conditioning; Yttrium Radioisotopes | 2006 |
Cure of incurable lymphoma.
Topics: Antibodies, Monoclonal; Clinical Trials, Phase III as Topic; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Radiopharmaceuticals; Radiotherapy Dosage; Yttrium Radioisotopes | 2006 |
Radioimmunotherapy for B-cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Humans; Immunoconjugates; Lymphoma, B-Cell; Radioimmunotherapy; Treatment Outcome; Yttrium Radioisotopes | 2006 |
Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antigens, CD20; Humans; Iodine Radioisotopes; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Radiopharmaceuticals; Radiotherapy Dosage; Remission Induction; Treatment Outcome; Yttrium Radioisotopes | 2007 |
Radiolabeled antibody therapy of B-cell lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Clinical Trials as Topic; Humans; Iodine Radioisotopes; Lymphoma, B-Cell; Radioimmunotherapy; Rituximab; Splenomegaly; Yttrium Radioisotopes | 1999 |
Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Humans; Immunologic Factors; Lymphoma, B-Cell; Radioimmunotherapy; Remission Induction; Rituximab; Yttrium Radioisotopes | 1999 |
Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Clinical Trials as Topic; Humans; Immunotoxins; Lymphoma, B-Cell; Radioimmunotherapy; Rituximab; Yttrium Radioisotopes | 2001 |
[Treatment of B-cell lymphoma with a chimeric anti-CD20 monoclonal antibody(rituximab)].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Immunoconjugates; Lymphoma, B-Cell; Mice; Radioimmunotherapy; Rituximab; Yttrium Radioisotopes | 2002 |
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antigens, CD20; Clinical Trials as Topic; Humans; Iodine Radioisotopes; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Quality of Life; Radioimmunotherapy; Radiopharmaceuticals; Radiotherapy Dosage; Yttrium Radioisotopes | 2002 |
Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Lymphoma, B-Cell; Neoplasm Recurrence, Local; Radioimmunotherapy; Randomized Controlled Trials as Topic; Rituximab; Treatment Outcome; Yttrium Radioisotopes | 2002 |
18 trial(s) available for yttrium radioisotopes and Lymphoma, B-Cell
| Article | Year |
|---|---|
Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Invasiveness; Podophyllotoxin; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult; Yttrium Radioisotopes | 2018 |
Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Chronic Disease; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Myeloablative Agonists; Radioimmunotherapy; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Yttrium Radioisotopes | 2015 |
Preliminary Experience with Yttrium-90-labelled Rituximab (Chimeric Anti CD-20 Antibody) in Patients with Relapsed and Refractory B Cell Non-Hodgkins Lymphoma.
Topics: Adult; Aged; Antigens, CD20; Antineoplastic Agents; Disease-Free Survival; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Radioimmunotherapy; Rituximab; Treatment Outcome; Young Adult; Yttrium Radioisotopes | 2016 |
Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in primary cutaneous B-cell lymphomas: first results of a prospective, monocentre study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Pilot Projects; Radioimmunotherapy; Remission Induction; Salvage Therapy; Skin Neoplasms; Treatment Outcome; Yttrium Radioisotopes | 2008 |
Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Radioimmunotherapy; Recurrence; Yttrium Radioisotopes | 2009 |
First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Central Nervous System Neoplasms; Female; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Radioimmunotherapy; Remission Induction; Survival Rate; Tissue Distribution; Yttrium Radioisotopes | 2009 |
Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study.
Topics: Antibodies, Monoclonal; Antigens, CD; Antigens, CD20; Disease Progression; Disease-Free Survival; Follow-Up Studies; Humans; Lymphoma, B-Cell; Radioimmunotherapy; Time Factors; Yttrium Radioisotopes | 2004 |
Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Cell Line, Transformed; Clinical Trials as Topic; Disease Progression; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Radioimmunotherapy; Remission Induction; Rituximab; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2004 |
Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antigens, CD20; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Thrombocytopenia; Yttrium Radioisotopes | 2004 |
A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma.
Topics: Adsorption; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Biotin; Biotinylation; Cell Line, Tumor; Clinical Trials as Topic; Hemadsorption; Humans; Immunoconjugates; Indium Radioisotopes; Kidney; Liver; Lymphoma, B-Cell; Radioimmunodetection; Radioimmunotherapy; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Rituximab; Time Factors; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2005 |
Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Dose-Response Relationship, Radiation; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Staging; Radioimmunotherapy; Recurrence; Reproducibility of Results; Tissue Distribution; Yttrium Radioisotopes | 2005 |
4. Antibody therapy for malignant lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Humans; Lymphoma; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Rituximab; Yttrium Radioisotopes | 2007 |
Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Immunoconjugates; Lymphoma, B-Cell; Neoplasm Recurrence, Local; Radioimmunotherapy; Rituximab; Yttrium Radioisotopes | 2007 |
Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cerebral Hemorrhage; Female; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Survival Analysis; Yttrium Radioisotopes | 2007 |
Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Stem Cell Transplantation; Transplantation, Autologous; Yttrium Radioisotopes | 2007 |
High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment.
Topics: Adult; Aged; Antibodies, Monoclonal; Dose-Response Relationship, Radiation; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Radioimmunotherapy; Tissue Distribution; Yttrium Radioisotopes | 2007 |
Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bone Marrow; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Radiometry; Rituximab; Yttrium Radioisotopes | 2000 |
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD19; Antineoplastic Agents; Cell Transformation, Neoplastic; Disease Progression; Disease-Free Survival; Female; Humans; Liver; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Radionuclide Imaging; Rituximab; Survival Rate; Treatment Outcome; Yttrium Radioisotopes | 2002 |
39 other study(ies) available for yttrium radioisotopes and Lymphoma, B-Cell
| Article | Year |
|---|---|
Real-world data from yttrium-90 ibritumomab tiuxetan treatment of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma: J3Zi Study.
Topics: Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Radioimmunotherapy; Retrospective Studies; Yttrium Radioisotopes | 2023 |
Theranostics in Hematooncology.
Topics: Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Positron Emission Tomography Computed Tomography; Precision Medicine; Radioimmunotherapy; Yttrium Radioisotopes | 2023 |
Radioimmunotherapy in allogeneic nonmyeloablative conditioning for B cell lymphoma: should we use it more often?
Topics: Antibodies, Monoclonal; Antigens, CD20; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Radioimmunotherapy; Survival Analysis; Transplantation Conditioning; Yttrium Radioisotopes | 2015 |
Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Humans; Lymphoma, B-Cell; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiation Dosage; Radioimmunotherapy; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Rituximab; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2015 |
p53-Based Strategy for Protection of Bone Marrow From Y-90 Ibritumomab Tiuxetan.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; Arsenic; Biomarkers; Bone Marrow; Bone Marrow Cells; DNA Damage; Female; Genes, p53; Glucose Transporter Type 1; Glucose Transporter Type 3; Heterografts; Histones; In Situ Nick-End Labeling; Lymphoma, B-Cell; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Radiation Dosage; Radiation Injuries, Experimental; Radiation Tolerance; Radiation-Protective Agents; Radioimmunotherapy; Transcriptional Activation; Yttrium Radioisotopes | 2015 |
Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation.
Topics: Alpha Particles; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Beta Particles; Dose-Response Relationship, Radiation; Female; Half-Life; Immunoconjugates; Lymphoma, B-Cell; Mice; Mice, Inbred C3H; Mice, Nude; Radioimmunotherapy; Relative Biological Effectiveness; Rituximab; Thorium; Transplantation, Heterologous; Yttrium Radioisotopes | 2008 |
Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab).
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD20; Cell Line, Tumor; Disease Models, Animal; Humans; Immunoglobulin G; Lymphoma, B-Cell; Male; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Sialic Acid Binding Ig-like Lectin 2; Yttrium Radioisotopes | 2008 |
[Recent topics in targeted radiotherapy: metastron, zevalin and thyroid cancer].
Topics: Antibodies, Monoclonal; Antigens, CD20; Bone Neoplasms; Brachytherapy; Contraindications; Humans; Lymphoma, B-Cell; Pain; Strontium Radioisotopes; Thyroid Neoplasms; Yttrium Radioisotopes | 2009 |
Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Topics: Aged; Analysis of Variance; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, B-Cell; Male; Positron-Emission Tomography; Prospective Studies; Radiographic Image Interpretation, Computer-Assisted; Radioimmunotherapy; Radiopharmaceuticals; ROC Curve; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2010 |
Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy.
Topics: Adolescent; Adult; Bone Marrow; Female; Humans; Lymphoma, B-Cell; Male; Radioimmunotherapy; Radiometry; Radiotherapy Dosage; Yttrium Radioisotopes | 2010 |
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome.
Topics: Adult; Aged; Antibodies, Monoclonal; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Staging; Radioimmunotherapy; Retrospective Studies; Time; Treatment Outcome; Yttrium Radioisotopes | 2010 |
Radioimmunotherapy with (90)Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network.
Topics: Adult; Antibodies, Monoclonal; Data Collection; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Male; Middle Aged; Radioimmunotherapy; Transplantation, Autologous; Treatment Outcome; Young Adult; Yttrium Radioisotopes | 2011 |
Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain; Cell Line, Tumor; Central Nervous System Neoplasms; Female; Humans; Lymphoma, B-Cell; Magnetic Resonance Imaging; Methotrexate; Random Allocation; Rats; Rats, Nude; Rituximab; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2011 |
Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with ⁹⁰Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Melphalan; Radioimmunotherapy; Treatment Outcome; Yttrium Radioisotopes | 2012 |
[Hematological toxicity of radioimmunotherpy with 90Y Ibritumomab].
Topics: Antibodies, Monoclonal; Hematologic Diseases; Humans; Lymphoma, B-Cell; Radioimmunotherapy; Yttrium Radioisotopes | 2012 |
Patient-specific whole-body attenuation correction maps from a CT system for conjugate-view-based activity quantification: method development and evaluation.
Topics: Female; Humans; Indium Radioisotopes; Iodine Radioisotopes; Lymphoma, B-Cell; Male; Neuroendocrine Tumors; Photons; Precision Medicine; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Scintillation Counting; Tomography, X-Ray Computed; Whole Body Imaging; Whole-Body Counting; Yttrium Radioisotopes | 2012 |
Immunotherapy for low-grade non-hodgkin secondary lymphoma of the orbit.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Female; Humans; Immunotherapy; Lymphatic Metastasis; Lymphoma, B-Cell; Male; Orbital Neoplasms; Rituximab; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2002 |
Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Female; Fever; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Radioimmunotherapy; Retrospective Studies; Salvage Therapy; Treatment Outcome; Yttrium Radioisotopes | 2002 |
Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas.
Topics: Animals; Antibodies, Monoclonal; Antigens, CD20; Biotin; Female; Humans; Indium Radioisotopes; Iodine Radioisotopes; Leukocyte Common Antigens; Lymphoma, B-Cell; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Organometallic Compounds; Radioimmunotherapy; Remission Induction; Streptavidin; Tumor Cells, Cultured; Yttrium Radioisotopes | 2003 |
Ibritumomab tiuxetan (Zevalin) for non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Drug Administration Schedule; Fees, Pharmaceutical; Half-Life; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Randomized Controlled Trials as Topic; Tachycardia; Yttrium Radioisotopes | 2002 |
90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Stability; Female; Heterocyclic Compounds, 1-Ring; Humans; In Vitro Techniques; Isotope Labeling; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pentetic Acid; Radioimmunotherapy; Radiopharmaceuticals; Reference Values; Tissue Distribution; Tumor Cells, Cultured; Yttrium Radioisotopes | 2003 |
Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Bone Marrow; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Male; Middle Aged; Radioimmunotherapy; Retrospective Studies; Syndrome; Treatment Outcome; Yttrium Radioisotopes | 2004 |
How and why does radioimmunotherapy work?
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Humans; Iodine Radioisotopes; Lymphoma, B-Cell; Radioimmunotherapy; Yttrium Radioisotopes | 2004 |
[Targeted destruction of lymphomas with the aid of radioimmunotherapy. Tumor antibodies isotope taxi].
Topics: Antibodies, Monoclonal; Antigens, CD20; Chelating Agents; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Radioimmunotherapy; Yttrium Radioisotopes | 2004 |
Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antigens, CD20; Disease Progression; Female; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Recurrence; Retrospective Studies; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2005 |
Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antigens, CD20; Disease Progression; Female; Gamma Cameras; Humans; Indium Radioisotopes; Lymphoma, B-Cell; Male; Middle Aged; Prognosis; Radioimmunotherapy; Radionuclide Imaging; Recurrence; Treatment Outcome; Yttrium Radioisotopes | 2005 |
[Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].
Topics: Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Agents; Humans; Iodine Radioisotopes; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Yttrium Radioisotopes | 2005 |
Myelosuppressive side-effects of radioimmunotherapy of non-Hodgkin's lymphoma: is there an increased risk?
Topics: Alkylating Agents; Antibodies, Monoclonal; Humans; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Prognosis; Radioimmunotherapy; Risk; Time Factors; Yttrium Radioisotopes | 2005 |
Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Cytotoxicity Tests, Immunologic; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Iodine Radioisotopes; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Rituximab; Yttrium Radioisotopes | 2005 |
Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Female; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Radiopharmaceuticals; Recurrence; Remission Induction; Yttrium Radioisotopes | 2006 |
Radioimmunotherapy in a radiation oncology environment: building a multi-specialty team.
Topics: Antibodies, Monoclonal; Humans; Interprofessional Relations; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Medical Oncology; Patient Care Team; Radiation Oncology; Radioimmunotherapy; Yttrium Radioisotopes | 2006 |
Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate.
Topics: Alpha Particles; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Cell Proliferation; Female; Humans; Immunoconjugates; Lymphoma, B-Cell; Mice; Mice, Inbred BALB C; Mice, Nude; Organometallic Compounds; Radioimmunotherapy; Rituximab; Survival Rate; Thallium Radioisotopes; Tissue Distribution; Tumor Cells, Cultured; Yttrium Radioisotopes | 2007 |
Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Radioimmunotherapy; Retrospective Studies; Yttrium Radioisotopes | 2007 |
B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience.
Topics: Adult; Aged; Antibodies, Monoclonal; Female; Humans; Image Processing, Computer-Assisted; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Positron-Emission Tomography; Radioimmunotherapy; Retrospective Studies; Tomography, Spiral Computed; Treatment Outcome; Yttrium Radioisotopes | 2008 |
Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Drug Interactions; Female; Humans; Immunoconjugates; Iodine Radioisotopes; Leukocyte Common Antigens; Lymphoma, B-Cell; Mice; Mice, Nude; Radioimmunotherapy; Rituximab; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2008 |
Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies.
Topics: Adult; Aged; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Radiography; Radioimmunotherapy; Recurrence; Yttrium Radioisotopes | 1996 |
Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antigens, CD20; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Radioimmunotherapy; Radiotherapy Dosage; Recurrence; Tissue Distribution; Yttrium Radioisotopes | 1996 |
Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.
Topics: Animals; Antibodies, Monoclonal; Antigens, CD20; Humans; Immunoglobulin G; Immunoglobulin kappa-Chains; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Mice; Mice, Inbred BALB C; Radioimmunotherapy; Tissue Distribution; Tumor Cells, Cultured; Yttrium Radioisotopes | 1999 |
Therapy of disseminated B-cell lymphoma xenografts in severe combined immunodeficient mice with an anti-CD74 antibody conjugated with (111)indium, (67)gallium, or (90)yttrium.
Topics: Animals; Antibodies; Antigens, Differentiation, B-Lymphocyte; Female; Gallium Radioisotopes; Histocompatibility Antigens Class II; Humans; Indium Radioisotopes; Lymphoma, B-Cell; Maximum Tolerated Dose; Mice; Mice, SCID; Neoplasm Transplantation; Protein Binding; Time Factors; Tumor Cells, Cultured; Yttrium Radioisotopes | 2001 |